BYSI

BeyondSpring Inc. (BYSI) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, primarily its lead asset Plinabulin. The company operates two segments: the Plinabulin pipeline (continuing operations) and the Targeted Protein Degradation (TPD) platform via its subsidiary SEED Therapeutics (discontinued operations). The TPD segment is being divested in a multi-tranche sale to third-party investors.

Key Financial Metrics

Note: Q1 2025 net income included a one-time gain of $6.986 million from the first closing of the SEED subsidiary sale.

Material Changes vs. Prior Period

• Net Loss vs. Income: The company reported a net loss of $6.7 million in Q1 2026 compared to net income of $1.2 million in Q1 2025. This shift is primarily due to the absence of the $7.0 million gain on the sale of SEED subsidiary interests recorded in the prior year.
• Operating Expenses: Continuing operations R&D expenses increased 23% to $1.1 million, driven by expanded drug manufacturing activities. G&A expenses decreased 33% to $1.2 million due to lower incentive compensation and professional fees.
• Liquidity: Cash and cash equivalents from continuing operations decreased by approximately $2.5 million quarter-over-quarter, reflecting ongoing operational burn rates.
• Discontinued Operations: SEED operations generated a loss of $4.3 million in Q1 2026, compared to a net income of $3.8 million in Q1 2025 (which included the sale gain).

Outlook, Risks, and Management Commentary

• Divestiture Progress: The company is executing a three-closing sale of its SEED subsidiary. The first closing ($7.4 million) occurred in February 2025. The second closing (approx. $13.2 million) is expected in 2026, and the third (approx. $14.9 million) is scheduled no later than December 15, 2026. Upon completion, the company expects to retain approximately 13.62% of SEED.
• Plinabulin Development: Management highlights the successful DUBLIN-3 Phase 3 study showing overall survival benefits in NSCLC. The company plans to file an NDA with China's NMPA and initiate a confirmatory global Phase 3 study (DUBLIN-4) in the U.S.
• Liquidity Outlook: Management anticipates current resources will fund operations for the next 12 months. However, substantial additional funding will be required for future clinical development and commercialization. The company is exploring equity/debt financing, partnerships, or asset sales.
• Risks: Key risks include the uncertainty of regulatory approvals, the ability to secure additional financing on acceptable terms, and the successful execution of the SEED divestiture. The company maintains a full valuation allowance against deferred tax assets.

Investor Verification Checklist

• SEED Divestiture Timeline: Verify the status and expected closing dates of the second and third tranches of the SEED sale to confirm future cash inflows.
• Cash Runway: Assess the burn rate of continuing operations against the $7.9 million liquidity position to validate the 12-month runway claim.
• Regulatory Filings: Monitor progress on the NDA filing with the NMPA for Plinabulin and the design of the DUBLIN-4 confirmatory study.
• Deferred Revenue: Review the $29 million deferred revenue from the Hengrui collaboration and the criteria for its recognition (unit of delivery measure).
• Debt Repayment: Note the $4.4 million repayment of short-term loans in discontinued operations financing activities and ensure no hidden liabilities remain in continuing operations.